Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Mobile Health on Improving Efficacy of Plaque Control in Antenatal Women With Gingivitis

NCT06997757 · tracked via the Priya Life Science India tracker
Phase
Not applicable
Started
2025-06-25
Last updated
2025-05-30

Condition(s) studied

Pregnancy Gingivitis

Investigational drug(s) / intervention(s)

Mobile healthPhase I Therapy

Mobile health: Instructions for brushing twice daily and using interdental cleaning aids via regular mobile phone messages will be sent atleast twice a week.

Phase I Therapy: Instructions for brushing twice daily and using interdental cleaning aids during appointment only.

Study summary

Oral health education, behavioral therapy and counselling to improve home care in pregnant females along with periodontal therapy can be helpful in treating pregnancy associated gingivitis and pregnancy outcomes

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
35 Years
Healthy volunteers
No
Inclusion Criteria: 1. Systemically Healthy pregnant women of age 18-35 years 2. 8-24 weeks of Gestation 3. Generalized gingivitis (BOP score \>30%s, without attachment loss and radiographic bone loss, PPD≤3mm) 4. Access to mobile phone 5. At least 20 natural teeth present Exclusion Criteria: 1. Presence of systemic diseases that could influence the outcome of periodontal therapy (Diabetes mellitus, Hypertension) 2. Smoking/alcohol consumption 3. Patient currently on any antibiotic therapy 4. Risk for Preterm Birth (Delivery \< 37 weeks of gestation) 5. History of periodontal treatment in the last 6 months 6. Physically and mentally impaired patients

Primary outcome measure(s)

  • Changes in the Plaque Index will be measured at baseline, 1 month follow up and at 3 month follow up. — 3 months
    Plaque Index as follows will be used for assessment of Plaque :- SCORE 0 : No Plaque SCORE 1: A film of plaque adhering to free gingival margin and adjacent area of the tooth recognized by running a probe SCORE 2 : Moderate accumulation of soft deposits within the gingival pockets or the tooth and gingival margin, which can be seen with naked eyes SCORE 3: Abundance of soft tissue matter on tooth surface and /or gingival margin
  • Changes in the Gingival Index will be measured at baseline, 1 month follow up and at 3 month follow up — 3 months
    Gingival Index by as follows will be used to assess severity of gingival inflammation:- SCORE 0 : Absence of inflammation SCORE 1: Mild inflammation SCORE 2 : Moderate inflammation SCORE 3: Severe inflammation
  • Changes in the Bleeding on Probing will be measured at baseline, 1 month follow up and at 3 month follow up — 3 months
    It will be measured by walking the periodontal probe at six sites of each tooth, it will be recorded as : 1- present , if it occurred within 15 seconds of probing 0- absent , if no bleeding occurred It will be calculated in %. After adding all the scores , total score will be divided by the total no. of surfaces assessed and multiplied by 100. It will be reported as % sites with bleeding on probing.

Trial sites (1)

FacilityCityRegionStatus
PGIDS Rohtak Haryana
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06997757 on ClinicalTrials.gov ↗ ← All trials in India